Process for preparing a pooled human platelet lysate, pooled human platelet lysate and its use for treating neurological disorders
Process for preparing a heat-treated pooled human platelet lysate, said process comprising the steps of: a) Providing a pooled human platelet lysate (p HPL), b) Heat-treating the pooled human platelet lysate at a temperature of 50° C. to 70° C. during 20 to 40 minutes, c) Purifying the heat-treated pooled human platelet lysate of step b).
1. A method for treatment of a neurological disorder, comprising the step of administering a heat-treated pooled human platelet lysate to a patient or subject in need thereof, wherein the heat-treated pooled human platelet lysate has a fibrinogen content of less than 5% by weight of the fibrinogen content of non-heat-treated pHPL and a fibrinogen content of less than 50 ng/mL.
2. The method according to claim 1 , wherein said heat-treated pooled human platelet lysate has a fibrinogen content of less than 3% by weight of the fibrinogen content of non-heat-treated pHPL and a fibrinogen content of less than 30 ng/mL.
3. The method according to claim 1 , wherein said heat-treated pooled human platelet lysate has a fibrinogen content of less than 1% by weight of the fibrinogen content of non-heat-treated pHPL and a fibrinogen content of less than 15 ng/mL.
4. The method according to claim 1 , wherein the neurological disorder is selected from neurodegenerative disorders, neuro inflammatory disorders, neurodevelopment disorders, neurovascular disorders and cerebral insults.
5. The method according to claim 4 , wherein the neurological disorder is a neurodegenerative disorder selected from multiple sclerosis (MS), Parkinson's disease (PD), Huntington's disease (HD), Amyotrophic lateral sclerosis (ALS), stroke, age-related macular degeneration (AMD), Alzheimer's disease (AD), vascular dementia, frontotemporal dementia, semantic dementia and dementia with Lewy bodies.
6. The method according to claim 5 , wherein the neurodegenerative disorder is selected from Parkinson's disease, amyotrophic lateral sclerosis, age-related macular degeneration and Alzheimer's disease.
7. The method according to claim 4 , wherein the neurological disorder is a cerebral insult selected from hypoxia or traumatic brain injury.
8. The method according to claim 1 , wherein said heat-treated pooled human platelet lysate is administrated by intrathecal, intraocular, intranasal or intra cerebroventricular route.
9. The method according to claim 8 , wherein said heat-treated pooled human platelet lysate is administrated by intra cerebroventricular route.
10. The method according to claim 9 , wherein said heat-treated pooled human platelet lysate is adapted to be administered with a programmable medication pump.
11. The method according to claim 8 , wherein said heat-treated pooled human platelet lysate is administrated into the right lateral ventricle.
12. The method according to claim 8 , wherein said heat-treated pooled human platelet lysate is administrated closed to the intraventricular foramen.
13. The method according to claim 8 , wherein said heat-treated pooled human platelet lysate is administrated into the third ventricle.